A Glasgow company has been awarded more than £1 million in fresh funding to further development of a single-dose cure for one of the world's deadliest diseases.

The $1.3m grant from the Gates Foundation will allow Keltic Pharma Therapeutics to accelerate its ground-breaking malaria drug discovery programme, which is based on work from the laboratories of Professor Andrew Tobin, Professor Andrew Jameson, and Professor Graeme Milligan at the University of Glasgow .

The company says its malaria treatment is within 12 months of what is known as "IND enablement", meaning Keltic will then be able to apply for approval for testing in humans.

Malaria causes more than 600,000 deaths globally each year, with children under five the most vulnerable. The resistance of the disease to current tr

See Full Page